4.3 Article

First hospitalization for heart failure in France in 2009: Patient characteristics and 30-day follow-up

期刊

ARCHIVES OF CARDIOVASCULAR DISEASES
卷 106, 期 11, 页码 570-585

出版社

ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.acvd.2013.08.002

关键词

Heart failure; Incidence; Hospitalization; France; SNIIRAM

资金

  1. AstraZeneca
  2. Daiichi-Sankyo
  3. Eli Lilly
  4. GSK
  5. Merck
  6. Novartis
  7. Pfizer
  8. Sanofi-Aventis
  9. Servier
  10. Medicines Company
  11. Bayer
  12. Bristol-Myers Squibb
  13. Boehringer Ingelheim
  14. GlaxoSmithKline
  15. MSD-Schering
  16. Novo Nordisk
  17. Roche
  18. Abbott Vascular
  19. Menarini
  20. Merck Sharp Dohme

向作者/读者索取更多资源

Background. - The incidence of heart failure (HF) is stable in industrialized countries, but its prevalence continues to increase, especially due to the ageing of the population, and mortality remains high. Objective. - To estimate the incidence in France and describe the management and short-term outcome of patients hospitalized for HF for the first time. Method. - The study population comprised French national health insurance general scheme beneficiaries (77% of the French population) hospitalized in 2009 with a principal diagnosis of HF after exclusion of those hospitalized for HF between 2006 and 2008 or with a chronic disease status for HE Data were collected from the national health insurance information system (SNIIRAM). Results. - A total of 69,958 patients (mean age 78 years; 48% men) were included. The incidence of first hospitalization for HF was 0.14% (>= 55 years, 0.5%; >= 90 years, 3.1%). Compared with controls without HF, patients more frequently presented cardiovascular or other co-morbidities. The hospital mortality rate was 6.4% and the mortality rate during the 30 days after discharge was 4.4% (3.4% without readmission). Among 30-day survivors, all-cause and HF 30-day readmission rates were 18% (<70 years, 22%; >= 90 years, 13%) and 5%, respectively. Reimbursements among 30-day survivors comprised at least a beta-blocker in 54% of cases, diuretics in 85%, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in 67%, a diuretic and ACEI/ARB combination in 23% and a beta-blocker, ACEI/ARB and diuretic combination in 37%. Conclusion. - Patients admitted for HF presented high rates of co-morbidity, readmission and death at 30 days, and there remains room for improvement in their drug treatments; these findings indicate the need for improvement in return-home and therapeutic education programmes. (C) 2013 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据